Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BFRI Biofrontera	$0.93 +1.4%	$0.80	$0.54 ▼ $2.22	$9.43M	0.5	247,067 shs	47,122 shs
COEP Coeptis Therapeutics	$11.18 +1.1%	$9.42	$2.31 ▼ $13.70	$39.24M	-0.59	83,920 shs	54,489 shs
LVTX LAVA Therapeutics	$1.53 +0.7%	$1.38	$0.85 ▼ $2.09	$40.25M	0.5	209,062 shs	22,972 shs
SLGL Sol-Gel Technologies	$15.25 -5.9%	$9.03	$3.61 ▼ $16.89	$42.55M	1.21	22,717 shs	30,002 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BFRI Biofrontera	-3.11%	-8.75%	+6.64%	+27.59%	-29.99%
COEP Coeptis Therapeutics	-0.90%	-4.24%	+17.52%	+12.28%	+173.76%
LVTX LAVA Therapeutics	-0.65%	+3.40%	+11.76%	+21.60%	-14.12%
SLGL Sol-Gel Technologies	+0.03%	+19.19%	+96.50%	+111.29%	+337.02%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BFRI Biofrontera	2.3235 of 5 stars	3.5	3.0	2.7	0.0	0.6
COEP Coeptis Therapeutics	0.6324 of 5 stars	0.0	3.0	2.7	1.7	0.0
LVTX LAVA Therapeutics	1.9018 of 5 stars	3.0	5.0	2.1	0.0	0.0
SLGL Sol-Gel Technologies	2.9294 of 5 stars	3.5	3.0	4.4	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BFRI Biofrontera	3.00	Buy	$2.75	195.70% Upside
COEP Coeptis Therapeutics	0.00	N/A	N/A	N/A
LVTX LAVA Therapeutics	2.00	Hold	$2.69	75.49% Upside
SLGL Sol-Gel Technologies	3.00	Buy	$40.00	162.30% Upside

Current Analyst Ratings Breakdown

Latest BFRI, COEP, LVTX, and SLGL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/5/2025	LVTX LAVA Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$1.50 ➝ $1.24
8/5/2025	LVTX LAVA Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$3.00 ➝ $1.50
5/19/2025	BFRI Biofrontera	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$7.00 ➝ $2.75
5/15/2025	LVTX LAVA Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform

(Data available from 8/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BFRI Biofrontera	$37.32M	0.25	N/A	N/A	$0.57 per share	1.63
COEP Coeptis Therapeutics	N/A	N/A	N/A	N/A	$1.61 per share	N/A
LVTX LAVA Therapeutics	$11.98M	3.36	N/A	N/A	$1.06 per share	1.44
SLGL Sol-Gel Technologies	$11.54M	3.69	N/A	N/A	$10.36 per share	1.47

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BFRI Biofrontera	-$17.76M	-$2.26	N/A	N/A	N/A	-30.33%	-305.13%	-82.67%	8/13/2025 (Estimated)
COEP Coeptis Therapeutics	-$10.88M	-$5.80	N/A	∞	N/A	N/A	-282.39%	-127.23%	N/A
LVTX LAVA Therapeutics	-$25.11M	-$1.04	N/A	N/A	N/A	N/A	-86.38%	-34.12%	8/19/2025 (Estimated)
SLGL Sol-Gel Technologies	-$10.58M	-$4.70	N/A	N/A	N/A	-107.78%	-43.98%	-35.28%	8/15/2025 (Estimated)

Latest BFRI, COEP, LVTX, and SLGL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/19/2025	Q2 2025	LVTX LAVA Therapeutics	-$0.28	N/A	N/A	N/A	N/A	N/A
8/13/2025	Q2 2025	BFRI Biofrontera	-$0.45	N/A	N/A	N/A	$8.30 million	N/A
5/23/2025	Q1 2025	SLGL Sol-Gel Technologies	N/A	-$3.20	N/A	-$3.20	N/A	$1.03 million
5/15/2025	Q1 2025	BFRI Biofrontera	-$0.14	-$0.47	-$0.33	-$0.47	$10.55 million	$8.59 million
5/14/2025	Q1 2025	COEP Coeptis Therapeutics	N/A	-$1.11	N/A	-$1.11	N/A	N/A
5/14/2025	Q1 2025	LVTX LAVA Therapeutics	-$0.37	-$0.13	+$0.24	-$0.13	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BFRI Biofrontera	N/A	N/A	N/A	N/A	N/A
COEP Coeptis Therapeutics	N/A	N/A	N/A	N/A	N/A
LVTX LAVA Therapeutics	N/A	N/A	N/A	N/A	N/A
SLGL Sol-Gel Technologies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BFRI Biofrontera	8.99	1.40	0.80
COEP Coeptis Therapeutics	0.02	0.82	0.82
LVTX LAVA Therapeutics	N/A	6.73	6.73
SLGL Sol-Gel Technologies	N/A	5.12	5.12

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BFRI Biofrontera	10.08%
COEP Coeptis Therapeutics	13.88%
LVTX LAVA Therapeutics	N/A
SLGL Sol-Gel Technologies	26.18%

Insider Ownership

Company	Insider Ownership
BFRI Biofrontera	4.80%
COEP Coeptis Therapeutics	24.25%
LVTX LAVA Therapeutics	9.50%
SLGL Sol-Gel Technologies	66.51%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BFRI Biofrontera	70	10.14 million	9.65 million	No Data
COEP Coeptis Therapeutics	2	3.51 million	2.66 million	Not Optionable
LVTX LAVA Therapeutics	60	26.31 million	23.81 million	Optionable
SLGL Sol-Gel Technologies	50	2.79 million	933,000	Optionable

BFRI, COEP, LVTX, and SLGL Headlines

Recent News About These Companies

Sol-Gel Technologies Ltd. (SLGL) Stock Price Today - WSJ

July 25, 2025 | wsj.com

Sol-Gel Technologies Ltd. (SLGL) - Yahoo Finance

July 9, 2025 | finance.yahoo.com

SLGL Sol-Gel Technologies Ltd. - Seeking Alpha

June 26, 2025 | seekingalpha.com

Sol-Gel Technologies Ltd

June 21, 2025 | morningstar.comM

Sol Gel Tech Stock Price History

June 1, 2025 | investing.com

Sol-Gel Technologies Ltd.: Sol-Gel Reports First Quarter 2025 Results

May 23, 2025 | finanznachrichten.de

Sol-Gel Stock Tumbles Over Underwhelming Q1 Earnings: Retail Stays Pessimistic

May 23, 2025 | msn.com

Sol-Gel Technologies Reports Q1 2025 Financial Results and Increased R&D Expenses

May 23, 2025 | quiverquant.comQ

Sol-Gel Reports First Quarter 2025 Results

May 23, 2025 | globenewswire.com

Insider Buying: Sol-Gel Technologies CEO & Executive Chairman Bought US$98k Of Shares

May 3, 2025 | uk.finance.yahoo.com

This Sol-Gel Technologies Insider Increased Their Holding In The Last Year

May 2, 2025 | finance.yahoo.com

Sol-Gel Announces Reverse Share Split

May 1, 2025 | globenewswire.com

Sol-Gel, Mayne Pharma enter product purchase agreement

April 17, 2025 | markets.businessinsider.com

Sol-Gel Technologies Ltd.: Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY and TWYNEO in the U.S.

April 17, 2025 | finanznachrichten.de

Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S.

April 17, 2025 | globenewswire.com

Global Sol-Gel Coatings Market Research 2025-2035: Competitive Landscape, Functional Properties and Applications, End-users, Technology Fundamentals, Overview and Growth Analysis

April 7, 2025 | globenewswire.com

Sol-Gel Technologies Approves Reverse Share Split and Compensation Policy Renewal

April 1, 2025 | tipranks.com

SLGL Gears Up to Report Q4 Earnings: Here's What You Should Know

February 25, 2025 | zacks.com

Is Sol-Gel Technologies (NASDAQ:SLGL) In A Good Position To Deliver On Growth Plans?

February 7, 2025 | finance.yahoo.com

Sol Gel Technologies Ltd (SLGL) Stock Trading Recap

December 26, 2024 | bovnews.comB

New MarketBeat Followers Over Time

Media Sentiment Over Time

BFRI, COEP, LVTX, and SLGL Company Descriptions

Biofrontera NASDAQ:BFRI

$0.93 +0.01 (+1.41%)

Closing price 04:00 PM Eastern

Extended Trading

$0.94 +0.01 (+1.29%)

As of 04:54 PM Eastern

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Coeptis Therapeutics NASDAQ:COEP

$11.18 +0.12 (+1.08%)

Closing price 04:00 PM Eastern

Extended Trading

$11.16 -0.03 (-0.22%)

As of 04:10 PM Eastern

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.

LAVA Therapeutics NASDAQ:LVTX

$1.53 +0.01 (+0.66%)

Closing price 04:00 PM Eastern

Extended Trading

$1.53 0.00 (0.00%)

As of 04:04 PM Eastern

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.

Sol-Gel Technologies NASDAQ:SLGL

$15.25 -0.95 (-5.86%)

Closing price 04:00 PM Eastern

Extended Trading

$15.08 -0.16 (-1.08%)

As of 04:40 PM Eastern

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time